ZENITH LABS ZEN WILL REPORT TH QTR LOSS RAMSEY N J March Zenith Laboratories Inc said the company will report a fourth quarter loss and the amount will be determined on completion of its year end audit The company did not elaborate further For the third quarter ended Sept Zenith reported a loss of dlrs or cts per share adjusted for a May for stock split The company also said it received Food and Drug Administration approval to market Cefadroxil a generic version of an antibiotic with domestic sales exceeding mln dlrs in Zenith said it will not market the drug until questions relating to the applicability of certain patents have been resolved Reuter